Association between antifibrotic medications and pneumothorax or pneumomediastinum in patients with idiopathic pulmonary fibrosis
T. Akamatsu (Shizuoka, Japan), H. Nakayasu (Shizuoka, Japan), K. Tamura (Shizuoka, Japan), T. Masuda (Shizuoka, Japan), S. Takahashi (Shizuoka, Japan), Y. Tanaka (Shizuoka, Japan), H. Watanabe (Shizuoka, Japan), Y. Kishimoto (Shizuoka, Japan), K. Oishi (Shizuoka, Japan), M. Saigusa (Shizuoka, Japan), A. Yamamoto (Shizuoka, Japan), S. Morita (Shizuoka, Japan), K. Asada (Shizuoka, Japan), T. Shirai (Shizuoka, Japan)
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Akamatsu (Shizuoka, Japan), H. Nakayasu (Shizuoka, Japan), K. Tamura (Shizuoka, Japan), T. Masuda (Shizuoka, Japan), S. Takahashi (Shizuoka, Japan), Y. Tanaka (Shizuoka, Japan), H. Watanabe (Shizuoka, Japan), Y. Kishimoto (Shizuoka, Japan), K. Oishi (Shizuoka, Japan), M. Saigusa (Shizuoka, Japan), A. Yamamoto (Shizuoka, Japan), S. Morita (Shizuoka, Japan), K. Asada (Shizuoka, Japan), T. Shirai (Shizuoka, Japan). Association between antifibrotic medications and pneumothorax or pneumomediastinum in patients with idiopathic pulmonary fibrosis. 1854
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: